PIK3CA and cancer: Similar approaches may also prove valuable to characterize the proteomic profiles associated with sensitivity among tumors that are negative for known PI3K pathway alterations—such as was seen in preclinical studies where capivasertib inhibited the growth of cancer cell lines without identifiable PI3K pathway alterations (47).